Collaborations

Kereos is committed to advancing its current candidates and future pipeline internally and in partnership with the leading imaging and therapeutic companies, and academic institutions. To date, the company has secured several such collaborations:

Bristol-Myers Squibb Medical Imaging (BMSMI)

Kereos and BMSMI are collaborating on the development and commercialization of KI-0002 and other cardiovascular disease molecular imaging agents using MRI.

Kereos has also licensed BMSMI avb3 ligands for use in KI-0001 and other product candidates.

Philips Medical Systems (Philips)

Kereos and Philips are collaborating on the development of molecular imaging agents, and hardware/software optimized for use with the Kereos agents.

  
The Dow Chemical Company

Kereos and Dow are working together to develop metal chelate technology for targeted imaging agents incorporated into Kereos’ product pipeline.

Washington University School of Medicine/Barnes-Jewish Hospital (WU/BJH)

Kereos has exclusively licensed from WU/BJH the ligand-targeted emulsion candidates and underlying technologies from the labs of Drs. Lanza and Wickline. Kereos and WU/BJH are collaborating on the development of these products, and the discovery of future candidates. As part of this relationship, Kereos is also working with The Dow Chemical Company and the National Cancer Institute.